References
- Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. J. Hepatol. 1997; 26(suppl 2)26–36, [PUBMED], [INFOTRIEVE]
- Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J. Clin. Epidemiol. 1993; 46(11)1331–1336, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Berardinis V. E., Moulis C., Maurice M., Beaune P., Pessayre D., Pompon D., Loeper J. Human microsomal epoxide hydrolyase is the target of germander‐induced autoantibodies on the surface of human hepatocytes. Mol. Pharmacol. 2000; 58: 542–551, [PUBMED], [INFOTRIEVE], [CSA]
- Danan G., Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug‐induced liver injuries. J. Clin. Epidemiol. 1993; 46(11)1323–1330, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Degott C., Feldmann G., Larrey D., Durand‐Schneider A. M., Grange D., Machayeki J. P., Moreau A., Potet F., Benhamou J. P. Drug‐induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 17: 244–251
- Desmet V. J. Vanishing bile duct syndrome in drug‐induced liver disease. J. Hepatol. 1997; 26(Suppl. 1)31–35, [PUBMED], [INFOTRIEVE]
- Estes J. D., Stolpman D., Olyaei A., Corless C. L., Ham J. M., Schwartz J. M., Orloff S. L. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch. Surg. 2003; 138: 852–858, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fau D., Lekehal M., Farrell G., Moreau A., Moulis C., Feldman G., Haouzi D., Pessayre D. Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 1997; 113: 1334–1346, [PUBMED], [INFOTRIEVE], [CSA]
- Favreau J. T., Mina L. R., Braunstein G., Orshansky G., Park S. S., Coody G. L., Love L. A., Fong T. L. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann. Intern. Med. 2002; 136: 590–595
- Graham D. J., Green L., Senior J. R., Nourjah P. Troglitazone‐induced liver failure: a case study. Am. J. Med. 2003; 114: 299–306, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Han D., Matsumaru K., Rettori D., Kaplowitz N. Usnic acid induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem. Pharmacol. 2004; 67: 439–451, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kaplowitz N. Drug‐induced liver disorders: implications for drug development and regulation. Drug Safety 2001a; 24(7)483–490, [PUBMED], [INFOTRIEVE], [CSA]
- Kaplowitz N. Causality assessment versus guilt by association in drug hepatotoxicity. Hepatology 2001b; 33: 308–310, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kaplowitz N. (2002a) Drug‐induced hepatocellular injury and cholestasis. Mechanisms of Acute and Chronic Liver Disease: Implications for Diagnosis, Pathogenesis, and Treatment. American Association for the Study of Liver Diseases Postgraduate Course 2002, Boston, MA, Nov, 1–22002, F. J. Suchy, J. G. Fitz, J. J. Maher. AASLD, Alexandria, VA, 79–86, Course Directors
- Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin. Liver Dis. 2002b; 22(2)137–144, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Larrey D., Vial T., Pauwels A., Castot A., Biour M., David M., Michel H. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann. Intern. Med. 1992; 117(2)129–132, [PUBMED], [INFOTRIEVE]
- Lasser K. E., Allen P. D., Woolhandler S. J., Himmelstein D. U., Wolfe S. M., Bor D. H. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215–2220, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lewis J. D., Strom B. L. Balancing safety of dietary supplements with the free market. Ann. Intern. Med. 2002; 136: 616–618, [PUBMED], [INFOTRIEVE]
- Liu Z. X., Kaplowitz N. Immune‐mediated drug‐induced liver disease. Clin. Liver Dis. 2002; 6: 755–774
- Loeper J., Descatoire V., Letteron P., Moulis C., Degott C., Dansette P., Fau D., Pessayre D. Hepatotoxicity of germander in mice. Gastroenterology 1994; 106: 464–472, [PUBMED], [INFOTRIEVE], [CSA]
- Lucena M. I., Camargo R., Andrade R. J., Peres‐Sanchez C. J., Sanchez F., Cuesta D. L. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123–130, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nierenberg D. W. “Did this drug cause my patient's hepatitis?” and related questions. Ann. Intern. Med. 2002; 136(6)480–483, [PUBMED], [INFOTRIEVE]
- Nolan C. M., Goldberg S. V., Buskin S. E. Hepatotoxicity associated with isoniazid preventive therapy: a 7‐year survey from a public health tuberculosis clinic. JAMA 1999; 228(23)2207–2208
- Ostapowicz G., Fontana R. J., Schiodt F. V., Larson A., Davern T. J., Han S. H.B., McCashland T. M., Shakil O., Hay E., Hynan L., Crippin J. S., Blei A. T., Samuel G., Reisch J., Lee W. M., the U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 2002; 137(12)947–954
- Watkins P. B., Whitcomb R. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 1998; 338: 916–917, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zimmerman H. Drug‐induced liver disease. Schiff's Diseases of Liver8th ed., E. Schiff, M. Sorrell, W. Maddrey. Lippincott‐Raven Publishers, Philadelphia, PA 1999; 973–1064